During the last session, 10x Genomics Inc (NASDAQ:TXG)’s traded shares were 3.84 million, with the beta value of the company hitting 1.99. At the end of the trading day, the stock’s price was $9.58, reflecting an intraday loss of -1.74% or -$0.17. The 52-week high for the TXG share is $38.49, that puts it down -301.77 from that peak though still a striking 3.24% gain since the share price plummeted to a 52-week low of $9.27. The company’s market capitalization is $1.17B, and the average intraday trading volume over the past 10 days was 2.85 million shares, and the average trade volume was 2.72 million shares over the past three months.
10x Genomics Inc (TXG) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 2.47. TXG has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
10x Genomics Inc (NASDAQ:TXG) trade information
10x Genomics Inc (TXG) registered a -1.74% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.74% in intraday trading to $9.58, hitting a weekly high. The stock’s 5-day price performance is -6.90%, and it has moved by -13.77% in 30 days. Based on these gigs, the overall price performance for the year is -73.60%. The short interest in 10x Genomics Inc (NASDAQ:TXG) is 12.08 million shares and it means that shorts have 3.63 day(s) to cover.
The consensus price target of analysts on Wall Street is $25, which implies an increase of 61.68% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $24 and $46 respectively. As a result, TXG is trading at a discount of -380.17% off the target high and -150.52% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -36.10%. While earnings are projected to return 1.74% in 2025, the next five years will return 17.46% per annum.
TXG Dividends
10x Genomics Inc is due to release its next quarterly earnings on 2025-Feb-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
10x Genomics Inc insiders own 2.75% of total outstanding shares while institutional holders control 96.93%, with the float percentage being 99.67%. FMR LLC is the largest shareholder of the company, while 379.0 institutions own stock in it. As of 2024-06-30, the company held over 13.01 million shares (or 10.836% of all shares), a total value of $253.05 million in shares.
The next largest institutional holding, with 10.19 million shares, is of VANGUARD GROUP INC’s that is approximately 8.5341% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $198.18 million.
Also, the Mutual Funds coming in first place with the largest holdings of 10x Genomics Inc (TXG) shares are ARK Innovation ETF and Vanguard Total Stock Market Index Fund . Data provided on Feb 28, 2025 indicates that ARK Innovation ETF owns about 9.42 shares. This amounts to just over 8.70 percent of the company’s overall shares, with a $90.26 million market value. The same data shows that the other fund manager holds slightly less at 3.18, or about 2.94% of the stock, which is worth about $30.49 million.
